Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.

MLA

Lion, Maëva, et al. “Trastuzumab as a Preoperative Monotherapy Does Not Inhibit HER2 Downstream Signaling in HER2-Positive Breast Cancer.” Oncology Letters, vol. 12, no. 3, Sept. 2016, pp. 2028–32. EBSCOhost, https://doi.org/10.3892/ol.2016.4891.

APA

Lion, M., Harlé, A., Salleron, J., Ramacci, C., Campone, M., & Merlin, J.-L. (2016). Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer. Oncology Letters, 12(3), 2028–2032. https://doi.org/10.3892/ol.2016.4891

Chicago

Lion, Maëva, Alexandre Harlé, Julia Salleron, Carole Ramacci, Mario Campone, and Jean-Louis Merlin. 2016. “Trastuzumab as a Preoperative Monotherapy Does Not Inhibit HER2 Downstream Signaling in HER2-Positive Breast Cancer.” Oncology Letters 12 (3): 2028–32. doi:10.3892/ol.2016.4891.